Abstract
Purpose
To investigate the therapeutic potential of extracellular vesicles (EVs) derived from human nucleus pulposus cells (NPCs), with a specific emphasis on Tie2-enhanced NPCs, compared to EVs derived from human bone marrow-derived mesenchymal stromal cells (BM-MSCs) in a coccygeal intervertebral disc degeneration (IDD) rat model.
Methods
EVs were isolated from healthy human NPCs cultured under standard (NPCSTD-EVs) and Tie2-enhancing (NPCTie2+-EVs) conditions. EVs were characterized, and their potential was assessed in vitro on degenerative NPCs in terms of cell proliferation and senescence, with or without 10 ng/mL interleukin (IL)-1β. Thereafter, 16 Sprague–Dawley rats underwent annular puncture of three contiguous coccygeal discs to develop IDD. Phosphate-buffered saline, NPCSTD-EVs, NPCTie2+-EVs, or BM-MSC-derived EVs were injected into injured discs, and animals were followed for 12 weeks until sacrifice. Behavioral tests, radiographic disc height index (DHI) measurements, evaluation of pain biomarkers, and histological analyses were performed to assess the outcomes of injected EVs.
Results
NPC-derived EVs exhibited the typical exosomal morphology and were efficiently internalized by degenerative NPCs, enhancing cell proliferation, and reducing senescence. In vivo, a single injection of NPC-derived EVs preserved DHI, attenuated degenerative changes, and notably reduced mechanical hypersensitivity. MSC-derived EVs showed marginal improvements over sham controls across all measured outcomes.
Conclusion
Our results underscore the regenerative potential of young NPC-derived EVs, particularly NPCTie2+-EVs, surpassing MSC-derived counterparts. These findings raise questions about the validity of MSCs as both EV sources and cellular therapeutics against IDD. The study emphasizes the critical influence of cell type, source, and culture conditions in EV-based therapeutics.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Low back pain (LBP) is the main cause of disability in the world [1] and is primarily triggered by intervertebral disc degeneration (IDD), a process characterized by catabolic events prompting extracellular matrix (ECM) degradation and cell loss, eventually altering disc morphology and biomechanics. To date, regenerative cell-based therapies are limited by poor post-transplantation viability, production scalability, and substantial donor variability [2]. Thus, cell-free therapeutics have been explored to overcome these hurdles. As anabolic effects exerted by transplanted cells are seemingly derived from their secretome, direct utilization of secreted factors may offer remarkable advantages over intradiscal cell delivery [3, 4]. In this context, extracellular vesicles (EVs) hold promise due to their role in intercellular communication and putative regenerative effects. With regard to IDD, mesenchymal stromal cell (MSC)-derived EVs have been demonstrated to reduce disc cell apoptosis, ECM degradation, tissue inflammation, and oxidative stress, both in vitro and in vivo [5].
Despite their notable chondrogenic potential, bone marrow-derived MSCs (BM-MSCs) exhibit significant differences from nucleus pulposus cell (NPC) progenitors [6], characterized by the expression of Tie2 receptors. Compared to Tie2−-NPCs, these cells have demonstrated higher self-renewal, proliferation, viability, and multidifferentiation potential, as well as increased ECM production [7, 8]. Recent studies have also demonstrated that NPCs expressing Tie2 present a superior chondrogenic differentiation capacity compared to BM-MSCs [9]. However, the percentage of Tie2+-NPCs is progressively exhausted with aging and advancing IDD, possibly explaining the limited ability of the IVD to perform self-repair [10].
Considering their regenerative capacity and recent advancements in culture methods to preserve Tie2 expression [11, 12], we sought to assess whether EVs secreted by this subpopulation might provide a promising cell-free therapy against IDD.
This study aimed to characterize and apply EVs derived from human NPCs cultured in standard and Tie2-enhancing conditions, to evaluate their biological effects in vitro, and to explore their regenerative potential in vivo.
Materials and methods
This study has been approved by the Institutional Review Board of Tokai University School of Medicine (Isehara, Kanagawa) under the approval number n. 221012. Informed consent for the collection and use of surgical waste products for research purposes was obtained from every patient. All animal experiments have been conducted according to the ARRIVE guidelines and in respect of the 3R principle. The detailed methodology is available as Supplementary Information.
Cell isolation and culture
Human IVD tissues were collected from surgical specimens at Tokai University Hospital (Isehara, Japan; Table 1). NPCs derived from young (mean age: 28.5 years) and healthy donors were cultured by standard non-Tie2-optimized (NPCSTD) or Tie2-enhancing culture strategies (NPCTie2; Fig. 1). Specimens were washed with phosphate-buffered saline (PBS), minced, and the NP tissue was carefully separated as previously described [7]. For NPCSTD, the tissue was digested in 0.25% trypsin–EDTA (Thermo Fisher, USA; 30 min, 37 °C), and then with 0.25 mg/mL collagenase P (Roche, Switzerland), Dulbecco’s Modified Eagle Medium-High Glucose (DMEM-HG; Wako, Japan), and 10% fetal bovine serum (FBS, Sigma-Aldrich, USA; 4 h, 37 °C). The yielded suspension was filtered through an 80-µm cell strainer and seeded on standard 100-mm dishes (~ 1 × 105 cells/dish). Following the guidelines of the Orthopedic Research Society (ORS) [13], NPCsSTD were cultured in DMEM-HG + 10% FBS + 1% penicillin/streptomycin (Gibco, USA) + 50 µg/mL L-ascorbic acid (Sigma-Aldrich) at 37 °C in 5% CO2 and 5% O2. The same protocol was adopted for NPCs from degenerative IVDs (dNPCs). After washing and mincing, the tissues undergoing the NPCsTie2+ culture approach were directly cultured in polystyrene six-well plates (IWAKI, Japan) with a commercially developed NPC-optimized, blended medium (MEMα:32%, DMEM:48%, FBS:20%; TUNZ Pharma Co., Ltd., Japan). Tissue fragments were cultured at 37 °C in 5% CO2 and 5% O2 for 14 days without media replenishment. Subsequently, cultured tissue fragments were digested as described above, and derived cells were seeded in monolayer at a density of 30,000 cells per 100-mm dish (545.5 cells/cm2) using the same medium [11]. A commercial cell line of human BM-MSCs (Poietics™, Lonza, USA) was cultured in DMEM-HG + 10% FBS + 1% penicillin/streptomycin at 37 °C in 5% CO2 and 21% O2 (Fig. 1).
EV isolation
FBS was ultracentrifuged (110,000 g for 17 h) and filtered through a 0.22-μm membrane to obtain bovine EV-free FBS [14]. NPCsSTD, NPCsTie2+, and BM-MSCs at 50–60% confluency were cultured with EV-free media for two days after which conditioned media were collected to isolate EVs as previously described [14]. Briefly, media were centrifuged at 1500 g (15 min), 12,000 g (30 min), and filtered with a 0.22-μm membrane to remove cell debris and larger vesicles. Eventually, the media were ultracentrifuged at 110,000 g (70 min) at 4 °C. The EV pellets were resuspended in PBS and ultracentrifuged again at 110,000 g (70 min) at 4 °C. The resulting EV products were used directly or stored at − 80 °C.
EV characterization
EV characterization was performed according to the International Society for Extracellular Vesicles guidelines [15], through transmission electron microscopy (TEM), single-particle analysis (qNano, Izon Science, New Zealand) [16] and assessment of CD63, CD9, TSG101, and lamin A/C expression by Western blot, comparing NPCs, BM-MSCs, and their EVs. EVs were quantified using the micro-bicinchoninic acid assay (Thermo Fisher).
EV uptake
NPCs were stained with Hoechst 33342 (Lonza), and isolated EVs were incubated with PKH26 (Sigma‐Aldrich) for 5 min. Labeled EVs were applied onto NPCs for 180 min, and uptake was observed through confocal laser scanning microscopy (LSM700, Carl Zeiss, Germany).
EV effect in vitro
dNPCs were cultured using standard media ± 10 ng/mL IL-1β (PeproTech, USA) to further promote catabolism [17]. Both conditions were treated with NPCSTD-EVs or NPCTie2+-EVs at 25, 50, 75, and 100 μg/mL [18]. Dose–effect at days three and seven of culture was determined through the CCK-8 assay (Dojindo, USA). Cell proliferation was calculated as percent change compared to the DMEM-only group.
Cell senescence
dNPCs were seeded into six-well plates (2.5 × 105 cells/well) and treated for 72 h with or without IL-1β and/or 50 µg/mL EVs as explained above. Subsequently, cells were washed with PBS, fixed, and incubated overnight with β-galactosidase staining (Cell Signaling, USA). Cells were observed under a phase-contrast light microscope, capturing six random fields per well at 10 × magnification, to determine the proportion of positive cells to total cells in a blinded manner.
Western blot
EVs and intact cells were lysed in RIPA buffer (Thermo Fisher). Protein lysates were resolved by SDS-PAGE using NuPAGE 4–12% Bis–Tris Gel (Invitrogen), MES running buffer, and blotted onto PVDF membranes. Membranes were incubated with primary antibodies (1:1000) at 4 °C overnight and secondary antibodies (1:2000) at room temperature for 1 h. The primary antibodies used were: CD9 (sc13118, Santa Cruz Biotechnology, USA), CD63 (BD556019, BD Biosciences, USA), TSG101 (ab30871, Abcam, UK), lamin A/C (MAB3211, Sigma-Aldrich), and GAPDH (SAB2108668, Sigma-Aldrich). Immunoreactive bands were detected using an Amersham Healthcare ECL Prime Western Blotting Detection Reagent (Cytiva, Japan). Protein signals were quantified by scanning densitometry (ATTO, Japan).
Assessment of EVs on in vivo IDD
Sixteen Sprague–Dawley rats (10 to 12 weeks old, MIZUSETSU, Japan) were randomly assigned to sham (n = 4), NPCSTD-EV (n = 4), NPCTie2+-EV (n = 4), or BM-MSC-EV (n = 4) groups (Fig. 2). Males were chosen due to reduced behavioral variability [19]. Following acclimation and baseline data acquisition, IDD was induced by annular puncture from Co5/6 to Co7/8 as previously described [20]. Co4/5 and Co8/9 functioned as healthy controls. Discs were surgically exposed, and approximately 10 μL of NP tissue was aspirated with a 21G needle. Subsequently, 2 μL of either PBS-only (sham group), NPCSTD-EVs, NPCTie2+-EVs, or BM-MSC-EVs was injected through a 27G needle–Hamilton syringe combination. Approximately 1.5 × 106 EVs were injected per level [21].
Behavioral assessment
Behavioral tests were performed at baseline and biweekly post-transplantation as previously described [22, 23]. Animals were placed in a 60 × 60 cm open-field box and recorded for 10 min from a bird’s eye view. The day before the test, animals were acclimatized in the enclosure for 10 min. Room lighting and time of day were kept consistent. EthoVision XT (Noldus Information Technology, The Netherlands) was used to analyze 18 parameters correlated with LBP as per previous studies [23].
The Von Frey test was performed using an esthesiometer (IITC, 2391). Three animals at a time were allowed to acclimate for 15 min in clear acrylic chambers placed on a metal grid. A maximum force of 28 g was applied ramping up over 10 s and kept for a maximum of 40 s. Withdraw threshold and time were assessed sequentially and alternatively by applying the probe on hind paws, tail base, and surgical site. This process was repeated at least thrice, and the averages were calculated. Investigators were blind to group allocation during the behavioral tests.
Serum biomarkers
Peripheral venous blood samples were obtained at baseline, 4, and 12 weeks post-operatively. Serum was isolated by centrifugation, frozen at − 80 °C, and used for IL-6 quantification using a rat-specific ELISA kit (RayBiotech, USA) as per the manufacturer’s instructions.
Radiographic assessment
Radiographic assessment was conducted at baseline and 4, 8, and 12 weeks post-operatively. Images were obtained from the coccygeal region with the animals in the supine position using a fluoroscopic imaging intensifier (DHF-105CX, Hitachi, Japan) under 2.5% isoflurane inhalation. In a blinded manner, disc height index (DHI) was calculated and normalized to pre-transplantation DHI [24].
Macroscopic and histological evaluation
At 12 weeks, the animals were sacrificed, tails were dissected, and discs were explanted. Samples were fixed in 10% formalin and decalcified using Wako solution A (Wako). Functional spine units were sectioned and assessed through Thompson grading system [25] by two blinded investigators. Subsequently, tissue sections were prepared for histology with hematoxylin/eosin, Safranin-O/Fast-Green, and Picrosirius-red/Aclian blue staining. Sections were blindly scored based on the ORS Spine rat histological grading scheme [26] by two investigators.
Statistical analysis
All quantitative data are expressed as means ± standard deviation. Data normal distribution was determined with the Wilk–Shapiro test. Statistical analysis was performed using one-way or two-way ANOVA. The Kruskal–Wallis test was performed to analyze non-normal data. Statistical significance was set as p < 0.05. Formal analysis was performed using Prism 10 (GraphPad, USA).
Results
EV isolation and characterization
TEM showed the typical EV oval cup morphology (Fig. 3a). NPCSTD-EVs, NPCTie2+-EVs, and BM-MSC-EVs exhibited an average diameter of 106.1 ± 16.3, 106.0 ± 18.2, and 87.0 ± 12.8 nm, respectively (Fig. 3b). The expression of EV markers CD63, CD9, and TSG101 was higher in EV samples compared to cell lysates, and lower for lamin A/C (Fig. 3c). PKH26-labeling showed EV uptake within NPCs (Fig. 3d). Collectively, these results demonstrated the isolation of small EVs (< 200 nm) with the characteristics of exosomes.
NPCSTD-EVs and NPCTie2+-EVs increased dNPC proliferation and reduced senescence
Dose–response evaluation of NPCSTD-EVs and NPCTie2+-EVs at day three showed that NPCTie2+-EVs significantly increased cell proliferation compared to NPCSTD-EVs at all concentrations (p < 0.05). Interestingly, the addition of IL-1β to NPCSTD-EVs (p < 0.05) and NPCTie2+-EVs (p < 0.01) further enhanced cell proliferation compared to NPCSTD-EVs alone (Fig. 4a). Similar results were observed at day seven (Fig. 4b). dNPCs treated with IL-1β showed an elongated, fibroblastic-like conformation, while NPCSTD-EV- and NPCTie2+-EV-treated cells exhibited a preserved morphology, even in the presence of IL-1β (Fig. 4c). Considering the lack of significant differences among tested EV concentrations, the intermediate value (50 μg/mL) was utilized in subsequent experiments. β-galactosidase staining (Fig. 5) demonstrated that NPCSTD-EVs and NPCTie2+-EVs significantly decreased senescent cell ratio compared to dNPCs cultured with IL-1β (p < 0.05). Furthermore, NPCTie2+-EVs prevented IL-1β-induced senescence (p < 0.05).
NPC-EVs decreased mechanical hypersensitivity and modulated pain-like behaviors in vivo
IDD induction and transplantation procedures were successfully performed without complications. Animals displayed stable weight without discernible differences among cohorts (Supplementary Fig. 1). The Von Frey test demonstrated that NPCSTD-EVs and NPCTie2+-EVs significantly lowered the nocifensive response threshold compared to the sham and BM-MSC-EV groups at the surgical site (Fig. 6a) and tail base (Fig. 6B; p < 0.05). Interestingly, NPCTie2+-EV-treated rats consistently exhibited the highest pain threshold and time until withdrawal (Supplementary Fig. 2a). No statistically significant differences were found following sham or BM-MSC-EV injections. No mechanical hypersensitivity was demonstrated for hind paws in any tested groups (Supplementary Fig. 2b).
The open field test, aimed to assess changes in spontaneous pain-like behavior, showed no evident between-group differences. Rats in the NPCSTD-EV and NPCTie2+-EV groups showed higher mean velocity, total distance, movement duration, behavioral probability of walking and rearing unsupported, walking frequency, and rearing unsupported duration and frequency, albeit failing to reach statistical significance (Fig. 7a–r). Although not showing significant differences, IL-6 serum levels displayed a more substantial decrease in NPCTie2+-EV-injected animals compared to the other groups (Fig. 7S).
NPCSTD-EVs and NPCTie2+-EVs maintained DHI
The sham group displayed a continuous DHI decrease, thus demonstrating successful IDD induction. BM-MSC-EV injection resulted in DHI reduction during the first eight weeks, with a slight non-significant increase at week 12. Interestingly, DHI in both NPC-EV groups did not display notable changes from baseline and was significantly higher than the sham and BM-MSC-EV groups (p < 0.05, Fig. 8).
NPCSTD-EVs and NPCTie2+-EVs preserved disc morphology
Gross IVD evaluation demonstrated significant degenerative alterations in the sham and BM-MSC-EV groups, while NPCSTD-EV and NPCTie2+-EV treatment preserved annulus fibrosus and nucleus pulposus morphology (Fig. 9a). Thompson scores for NPCSTD-EV- and NPCTie2+-EV-treated discs were significantly lower than in the sham and BM-MSC-EV groups (p < 0.01; Fig. 9b). Histological assessment confirmed these observations (Fig. 9c), with similarly lower scores for NPCSTD-EV and NPCTie2+-EV groups compared to both sham and BM-MSC-EV groups, although significant differences were obtained only compared to the former (p < 0.05; Fig. 9d).
Discussion
In this study, we showed that NPC-EVs were able to promote dNPC proliferation and reduce senescence in vitro while ameliorating pain and attenuating IDD in vivo. Moreover, we demonstrated that implementing a Tie2-enhancing protocol could augment NPC-EV therapeutic potential, emphasizing the importance of optimizing culture conditions.
Tie2 expression is associated with a progenitor phenotype characterized by multipotency and self-renewal capacity. The number of Tie2+-NPCs decreases with age and advancing IDD, possibly explaining the progressive reduction of the IVD inherent self-repair capacity [7]. Therefore, Tie2+-NPCs may constitute a potent cell source for IVD regeneration [11]. Recent evidence has demonstrated that EVs function as vectors of anabolic and anticatabolic mediators secreted by cells exploited as transplantation products to treat IDD. Indeed, EVs carry several biomolecules involved in cell communication, fate, and metabolism [18]. Furthermore, the EV cargo directly reflects the pathophysiological state of the donor cell, hence modulating the target cell response accordingly [27]. We postulated that increasing Tie2 expression in NPCs before EV isolation would promote the acquisition of a cargo with enhanced regenerative properties. According to our results, NPCTie2+-EVs exhibited the highest reparative capacity, although slightly superior to NPCSTD-EVs. By being isolated from relatively healthy NPCs, the intrinsic Tie2 expression and/or metabolic state of donor cells might equally result in the acquisition of an anabolic EV cargo.
Furthermore, our study revealed intriguing insights into pain-related behaviors. While the Von Frey test successfully demonstrated a reduction in mechanical hypersensitivity by NPC-EVs, other behavioral outcomes and systemic levels of IL-6 did not yield significant differences, similar to previous studies [22, 23]. This could be attributed to the specific nature of tail IDD pain, which might not exert a substantial impact on overall behavior, especially considering the tail’s limited weight-bearing role. Additionally, the acute degeneration model employed might not fully replicate the complex environment necessary to mimic discogenic pain [28].
Differently from previous studies, no significant beneficial outcomes of BM-MSC-EVs were found in vivo. Indeed, it has been earlier shown that BM-MSC-EVs were able to blunt ECM degradation, decrease disc cell loss, and dampen tissue inflammation and oxidative stress [18]. These differences could stem from several variables, including variations in cell sources, donor characteristics, and culture conditions. Nonetheless, while previous studies reported the use of repeated EV injections to achieve their therapeutic outcomes [18], a single injection of our NPC-derived EV product yielded a significant regenerative effect. These discrepancies, coupled with the wide variability among EV doses, units applied (protein vs. nanoparticle concentration), and inaccurate reporting in previous studies [18], emphasize the urgent need to establish an optimal dosing regimen for EV-based products.
While the caudal IVDs offer accessibility, established efficacy for evaluating intradiscally delivered treatments, and reproducibility, it is worth noting that the tail puncture model employed in this study has inherent limitations. Indeed, this model cannot fully replicate the complexity of chronic human lumbar IDD, particularly in terms of variations in cell types (such as notochordal cells in rats vs. human NPCs [29]) and biomechanical factors. These disparities may restrict the comprehensive understanding of the regenerative potential of our EV product in a real-world scenario. Another crucial factor to address is the xenogeneic nature of our EV transplantation (i.e., human to rat), potentially triggering an immunogenic response. However, our study did not find a reaction to our transplant product. This is in line with previous research that convincingly showed that EVs, either administered locally or systemically, did not provoke significant toxic or immunogenic reactions among different species [18, 30]. Therefore, we do not view this as a substantial concern. Although showing promising regenerative outcomes, the cargo of our EV product has not been specifically characterized. Unraveling the specific EV content will be essential to describe and predict its eventual effects. Moreover, additional in vitro experiments are needed to characterize the interaction between EVs and target cells, involved pathways, and mechanisms of action.
In summary, our study demonstrated NPC-EV therapeutic potential, highlighting the regenerative prowess of EVs isolated from NPCTie2+. These EVs countered IL-1β-induced catabolic effects in vitro and preserved DHI and tissue morphology in vivo. Despite promising outcomes, clinical translation of EV products will demand extensive research, including cargo characterization and standardization.
References
Ferreira ML, de Luca K, Haile LM, Steinmetz JD, Culbreth GT, Cross M et al (2023) Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 5:e316–e329. https://doi.org/10.1016/s2665-9913(23)00098-x
Vadala G, Ambrosio L, Russo F, Papalia R, Denaro V (2021) Stem cells and intervertebral disc regeneration overview-what they can and can’t do. Int J Spine Surg 15:40–53. https://doi.org/10.14444/8054
Tilotta V, Vadalà G, Ambrosio L, Cicione C, Di Giacomo G, Russo F et al (2023) Mesenchymal stem cell-derived secretome enhances nucleus pulposus cell metabolism and modulates extracellular matrix gene expression in vitro. Front Bioeng Biotechnol. https://doi.org/10.3389/fbioe.2023.1152207
Vadala G, Russo F, Ambrosio L, Di Martino A, Papalia R, Denaro V (2015) Biotechnologies and biomaterials in spine surgery. J Biol Regul Homeost Agents 29:137–147
Liang W, Han B, Hai Y, Sun D, Yin P (2022) Mechanism of action of mesenchymal stem cell-derived exosomes in the intervertebral disc degeneration treatment and bone repair and regeneration. Front Cell Dev Biol. https://doi.org/10.3389/fcell.2021.833840
Morita K, Schol J, Volleman TNE, Sakai D, Sato M, Watanabe M (2021) Screening for growth-factor combinations enabling synergistic differentiation of human msc to nucleus pulposus cell-like cells. Appl Sci. https://doi.org/10.3390/app11083673
Sakai D, Schol J, Bach FC, Tekari A, Sagawa N, Nakamura Y et al (2018) Successful fishing for nucleus pulposus progenitor cells of the intervertebral disc across species. Jor Spine. https://doi.org/10.1002/jsp2.1018
Guerrero J, Hackel S, Croft AS, Albers CE, Gantenbein B (2021) The effects of 3D culture on the expansion and maintenance of nucleus pulposus progenitor cell multipotency. JOR Spine 4:e1131. https://doi.org/10.1002/jsp2.1131
Li XC, Tang Y, Wu JH, Yang PS, Wang DL, Ruan DK (2017) Characteristics and potentials of stem cells derived from human degenerated nucleus pulposus: potential for regeneration of the intervertebral disc. BMC Musculoskelet Disord 18:242. https://doi.org/10.1186/s12891-017-1567-4
Sakai D, Nakamura Y, Nakai T, Mishima T, Kato S, Grad S et al (2012) Exhaustion of nucleus pulposus progenitor cells with ageing and degeneration of the intervertebral disc. Nat Commun 3:1264. https://doi.org/10.1038/ncomms2226
Sako K, Sakai D, Nakamura Y, Schol J, Matsushita E, Warita T et al (2021) Effect of whole tissue culture and basic fibroblast growth factor on maintenance of Tie2 molecule expression in human nucleus pulposus cells. Int J Mol Sci. https://doi.org/10.3390/ijms22094723
Soma H, Sakai D, Nakamura Y, Tamagawa S, Warita T, Schol J et al (2023) Recombinant laminin-511 fragment (iMatrix-511) Coating supports maintenance of human nucleus pulposus progenitor cells in vitro. Int J Mol Sci. https://doi.org/10.3390/ijms242316713
Basatvat S, Bach FC, Barcellona MN, Binch AL, Buckley CT, Bueno B et al (2023) Harmonization and standardization of nucleus pulposus cell extraction and culture methods. Jor Spine. https://doi.org/10.1002/jsp2.1238
Ito M, Kudo K, Higuchi H, Otsuka H, Tanaka M, Fukunishi N et al (2021) Proteomic and phospholipidomic characterization of extracellular vesicles inducing tumor microenvironment in Epstein-Barr virus-associated lymphomas. FASEB J. https://doi.org/10.1096/fj.202002730R
Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7:1535750. https://doi.org/10.1080/20013078.2018.1535750
Kakizaki M, Yamamoto Y, Otsuka M, Kitamura K, Ito M, Kawai HD et al (2020) Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model. J Biol Chem 295:12449–12460. https://doi.org/10.1074/jbc.RA120.014317
Vadalà G, Di Giacomo G, Ambrosio L, Cicione C, Tilotta V, Russo F et al (2022) The effect of Irisin on human nucleus pulposus cells: new insights into the biological crosstalk between the muscle and intervertebral disc. Spine. https://doi.org/10.1097/brs.0000000000004488
DiStefano TJ, Vaso K, Danias G, Chionuma HN, Weiser JR, Iatridis JC (2021) Extracellular vesicles as an emerging treatment option for intervertebral disc degeneration: therapeutic potential, translational pathways, and regulatory considerations. Adv Healthc Mater. https://doi.org/10.1002/adhm.202100596
Mosley GE, Wang M, Nasser P, Lai A, Charen DA, Zhang B et al (2020) Males and females exhibit distinct relationships between intervertebral disc degeneration and pain in a rat model. Sci Rep 10:15120. https://doi.org/10.1038/s41598-020-72081-9
Schol J, Sakai D, Warita T, Nukaga T, Sako K, Wangler S et al (2022) Homing of vertebral-delivered mesenchymal stromal cells for degenerative intervertebral discs repair—an in vivo proof-of-concept study. Jor Spine. https://doi.org/10.1002/jsp2.1228
Barcellona MN, McDonnell EE, Samuel S, Buckley CT (2022) Rat tail models for the assessment of injectable nucleus pulposus regeneration strategies. Jor Spine. https://doi.org/10.1002/jsp2.1216
Lillyman DJ, Lee FS, Barnett EC, Miller TJ, Alvaro ML, Drvol HC et al (2022) Axial hypersensitivity is associated with aberrant nerve sprouting in a novel model of disc degeneration in female Sprague Dawley rats. Jor Spine. https://doi.org/10.1002/jsp2.1212
Wawrose RA, Couch BK, Dombrowski M, Chen SR, Oyekan A, Dong Q et al (2022) Percutaneous lumbar annular puncture: a rat model to study intervertebral disc degeneration and pain-related behavior. Jor Spine. https://doi.org/10.1002/jsp2.1202
Hiraishi S, Schol J, Sakai D, Nukaga T, Erickson I, Silverman L et al (2018) Discogenic cell transplantation directly from a cryopreserved state in an induced intervertebral disc degeneration canine model. Jor Spine. https://doi.org/10.1002/jsp2.1013
Thompson JP, Pearce RH, Schechter MT, Adams ME, Tsang IKY, Bishop PB (1990) Preliminary evaluation of a scheme for grading the gross morphology of the human intervertebral disc. Spine 15:411–415. https://doi.org/10.1097/00007632-199005000-00012
Lai A, Gansau J, Gullbrand SE, Crowley J, Cunha C, Dudli S et al (2021) Development of a standardized histopathology scoring system for intervertebral disc degeneration in rat models: an initiative of the ORS spine section. Jor Spine. https://doi.org/10.1002/jsp2.1150
Tilotta V, Vadalà G, Ambrosio L, Di Giacomo G, Cicione C, Russo F et al (2023) Wharton’s Jelly mesenchymal stromal cell-derived extracellular vesicles promote nucleus pulposus cell anabolism in an in vitro 3D alginate-bead culture model. Jor Spine. https://doi.org/10.1002/jsp2.1274
Diwan AD, Melrose J (2022) Intervertebral disc degeneration and how it leads to low back pain. Jor Spine. https://doi.org/10.1002/jsp2.1231
Williams RJ, Laagland LT, Bach FC, Ward L, Chan W, Tam V et al (2023) Recommendations for intervertebral disc notochordal cell investigation: From isolation to characterization. Jor Spine. https://doi.org/10.1002/jsp2.1272
Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A et al (2017) Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J Extracell Vesicles. https://doi.org/10.1080/20013078.2017.1324730
Acknowledgments
The authors would like to thank Erika Matsushita, Takayuki Warita, Asami Kawachi, Takuma Araki, Misaki Higashiseto, Shunji Amano, Yuka Kitamura, Masatoshi Ito, Shuho Hori, Nahoko Fukunishi, and Ai Kotani for the support provided during the study. We would also like to acknowledge the Support Center for Medical Research and Education at Tokai University (Isehara, Japan) for their support with animal experimentation and sample processing.
Funding
This study was supported by a grant from the ON Foundation, Switzerland, under the project n. 22–199 and by the “Patrizio Parisini” prize provided by the Italian Society of Spine Surgery & Italian Scoliosis Group (SICV&GIS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
HS is a paid employee of TUNZ Pharma Co., Ltd. (Osaka, Japan). DS is a scientific advisor of TUNZ Pharma Co., Ltd.
Ethical approval
This study has been approved by the Institutional Review Board of Tokai University School of Medicine (Isehara, Kanagawa) under the approval number n. 221012. Informed consent for the collection and use of surgical waste products for research purposes was obtained from every patient. All animal experiments have been conducted according to ARRIVE guidelines and in respect of the 3R principle.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material:
586_2024_8163_MOESM1_ESM.tiff
Supplementary Fig. 1 Evaluation of rats’ body weight throughout the whole duration of the study. Body weight progressively increased in all animals without showing any significant or pathological change. N = 4 animals per group.
Supplementary file1 (TIFF 2753 kb)
586_2024_8163_MOESM2_ESM.tiff
Supplementary Fig. 2 Results of the Von Frey test to evaluate mechanical pain hypersensitivity in terms of reaction time (a) at the surgical site and tail base. NPCTie2+-EV-treated rats consistently exhibited the highest time until withdrawal. (b) Evaluation of mechanical allodynia at hind paws did not show any significant differences among groups. N = 4 animals per group. Abbreviations: NPCTie2+-EVs extracellular vesicles isolated from nucleus pulposus cells cultured in Tie2-enhancing conditions
Supplementary file2 (TIFF 7005 kb)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ambrosio, L., Schol, J., Ruiz-Fernandez, C. et al. ISSLS PRIZE in Basic Science 2024: superiority of nucleus pulposus cell- versus mesenchymal stromal cell-derived extracellular vesicles in attenuating disc degeneration and alleviating pain. Eur Spine J 33, 1713–1727 (2024). https://doi.org/10.1007/s00586-024-08163-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00586-024-08163-3